The increasing number of genome-wide transcriptome analyses focusing on p53-induced cellular responses in many cellular contexts keeps adding to the already numerous p53-regulated transcriptional networks. To investigate post-transcriptional controls as an additional dimension of p53-directed gene expression responses, we performed a translatome analysis through polysomal profiling on MCF7 cells upon 16 hours of doxorubicin or nutlin-3a treatment. The comparison between the transcriptome and the translatome revealed a considerable level of uncoupling, characterized by genes whose transcription variations did not correlate with translation variations. Interestingly, uncoupled genes were associated with apoptosis, DNA and RNA metabolism and cell cycle functions, suggesting that post-transcriptional control can modulate classical p53-regulated responses. Furthermore, even for well-established p53 targets that were differentially expressed both at the transcriptional and translational levels, quantitative differences between the transcriptome, subpolysomal and polysomal RNAs were evident. As we searched mechanisms underlying gene expression uncoupling, we identified the p53-dependent modulation of six RNA-binding proteins, where hnRNPD (AUF1) and CPEB4 are direct p53 transcriptional targets, whereas SRSF1, DDX17, YBX1 and TARDBP are indirect targets (genes modulated preferentially in the subpolysomal or polysomal mRNA level) modulated at the translational level in a p53-dependent manner. In particular, YBX1 translation appeared to be reduced by p53 via two different mechanisms, one related to mTOR inhibition and the other to miR-34a expression. Overall, we established p53 as a master regulator of translational control and identified new p53-regulated genes affecting translation that can contribute to p53-dependent cellular responses.
Discovered nearly 35 years ago, tumor suppressor p53, which is often described as the 'guardian of the genome,' acts prominently as a transcription factor in many biological processes including DNA metabolism, apoptosis and cell cycle regulation. 1 Although the role of p53 is generally considered to be at the level of transactivation via binding to target sequences, there are several other ways by which it can determine its cellular responses including, for example, interaction with other transcription factors. 2 Post-transcriptional and translational controls provide fine tuning of transcriptional outcomes in eukaryotic somatic cells. 3 More than 90% of all coding transcripts appear to be subject to this regulation, especially at translation initiation, 4 considered as the rate-limiting step of the whole process. 3, 5 By binding mainly to the 5 0 and 3 0 untranslated regions (5 0 UTR; 3 0 UTR) of mRNAs, miRNAs-other non-coding RNAs and RNA-binding proteins (RBPs)-were shown to participate in the regulation of translation. 6 An unexpected complexity in the modulation of the fate of mRNAs along with a widespread alteration of that process in cancer cells was found in recent studies. [7] [8] [9] The synthesis of the p53 protein itself has been shown to be modulated by miR-125b 10 or by RPL26 and nucleolin, that produce opposite effects on the rate of p53 mRNA translation. 11 Moreover, p53 target genes, including CDKN1A (p21), BBC3 (PUMA) and BAX, can be regulated post-transcriptionally by miRNAs or RBPs, some of which can be direct p53 target genes. The impact that this additional level of regulation can have on the p53 response networks has been recently reviewed. [12] [13] [14] [15] [16] [17] All these mechanisms to control the fate of mRNAs may account for the lack of correlation-referred to as uncouplingbetween relative changes in the total cellular mRNA levels (corresponding to the transcriptome (transcripts examined from total RNA extractions)) and protein abundances (the proteome) after p53 activation. 18 To investigate p53-dependent uncoupling at the genome level, we compared the transcriptome after doxorubicin (Doxo) or nutlin-3a (Nutlin) treatment with the translatome (transcript examined from polysomal mRNA extractions, considered as actively translated), analyzed by polysomal profiling, a technique that allows quantification of mRNAs associated with the polysomes as a proxy for the proteome. 19 Overall, we identified an evident translation selectivity that we considered to be an additional dimension by which p53 can tailor its gene response network.
Results
Coupled differentially expressed genes after doxorubicin and nutlin-3a treatments are enriched for p53 targets. To characterize the impact of post-transcriptional regulation in shaping the p53-dependent gene response, we combined polysomal profiling with microarray analysis on MCF7vector cells 20 (containing wild-type p53) upon doxorubicin (Doxo, 1.5 mM) or nutlin-3a (Nutlin, 10 mM) treatment for 16 h. Both treatments resulted in high p53 induction and similar low levels of toxicity (Supplementary Figure S1 ). Experiments were conducted also on MCFshp53 cells, which express an shRNA targeting p53. 20 Residual p53 expression was detected in MCF7shp53 cells, but p21 was not induced by either Doxo or Nutlin (Supplementary Figure S1C) .
No significant effects of the treatments on overall polysomal distributions were evident (Figure 1a) . For the microarray analysis, we collected subpolysomal ('sub') and polysomal ('pol') mRNA fractions so as to analyze mRNAs that are not actively translated separately from those that are in active translation. 21 Total mRNA ('tot') was also collected to quantify transcriptome changes (see Materials and Methods).
When we measured the global overlap between expression changes of 'tot' (transcriptome) and 'pol' (translatome), we obtained Spearman correlations of 0.65 and 0.67 after Doxo and Nutlin treatment, respectively ( Figure 1b) . Hence, many genes exhibited homodirectional changes both in terms of transcriptome and translatome (defined as coupled differentially expressed genes (DEGs)). In the three RNA preparations (tot, pol and sub), we found 239 and 155 commonly upregulated coupled DEGs (DEGs with homodirectional expression changes in transcriptome and translatome) after Doxo and Nutlin treatment and 216 and 301 commonly repressed coupled DEGs (Figure 1c , green, overlapping areas). Among them, we counted 107 upregulated coupled and 118 downregulated-coupled DEGs in both Doxo and Nutlin treatment. (Supplementary Table S1A ). A p53 pathway signature was revealed by ingenuity pathway analysis for Doxo and Nutlin upregulated and downregulated coupled DEGs (Figure 1d ). Sixty-four out of 225 genes had expression changes consistent with p53 activation (P-value: 7.5 À 39 ) (Supplementary Table S2A ). Moreover, ingenuity pathway analysis identified p53 as the main upstream regulator especially among coupled DEGs (Supplementary Table S3) . Interestingly, gene ontology enrichment did not reveal differences between Doxo and Nutlin DEGs (Supplementary  Table S2B ), consistent with the similarity in cell phenotypes observed at the doses and time point used (Supplementary Figure S1) .
Three well-established p53 target genes (MDM2, p21 and PUMA) were validated as coupled DEGs by quantitative PCR (qPCR), whose sensitivity is higher than the microarray's (Figure 1e ). Given the significantly higher fold change in the pol fraction compared with the subpolysomal fraction, particularly after Nutlin treatment, p21 and MDM2 translation appeared to be enhanced. We defined this finding a 'translational thrust'. An 8 h treatment time point was added for comparison ( Figure 1e) ; (Supplementary Figure S2) . At the earlier time point the induction of the three p53 target genes, and particularly MDM2, was more robust in response to Nutlin than to Doxo. The PUMA transcript can also be classified as a thrust gene after 8 h of Nutlin treatment. However, at the 16 h time point PUMA-relative expression changes were higher in total RNA compared with sub and pol, suggesting that, unlike MDM2 and p21, the PUMA transcript could be subject to an opposite regulation we define here as 'translational drag.' This latter phenomenon could be dependent on several factors, including delayed transactivation, slow pre-mRNA maturation, regulation at the nuclear export level or slow assembly of ribosomes on mRNAs. No evidence of transcriptional or translational changes was seen in treated MCF7shp53 cells (Figure 1e ).
The majority of direct p53 target genes are coupled. Nevertheless, we found that expression is uncoupled for about 70% of DEGs.
The uncoupled, translationally upregulated gene group is enriched for apoptotic functions. Uncoupled DEGs are genes with a major change in relative expression levels compared with mock treatment in only one of the three mRNA preparations: (a) transcriptome (tot); (b) translatome (pol); (c) non-translated subpolysomal mRNAs (sub) (red, blue and yellow circular sectors, respectively, in Figure 1c ). We identified 1432 uncoupled DEGs after Doxo and 987 after Nutlin treatment.
First, we focused on uncoupled DEGs that were induced in the translatome but did not change in the transcriptome ( Figure 2a) ; (Supplementary Table S1B ). We found 55 translatome-uncoupled DEGs common to the two treatments ( Figure 2a ). Among them, PHPT1 (14-kDa phosphohistidine phosphatase) 22 and TP53RK (p53-related protein kinase) 23 were chosen for validation by qPCR owing to their biological relevance in post-translational control, and because they had not been previously reported as p53-regulated genes. PHPT1 and TP53RK proved to be translational upregulated genes, particularly after 16 h of treatment ( Figure 2b ). We also compared changes in protein levels by western blot analysis (Figure 2c ). Considered as a proxy of the proteome, the pol level should reflect the protein level of each transcript. PHPT1 protein levels were slightly induced by both Doxo and Nutlin in MCF7vector cells, whereas no changes occurred in MCF7shp53 (the basal levels were significantly lower) (Figures 2b and c) .
Among induced translatome-uncoupled DEGs, gene ontology analysis revealed enrichment for apoptosis terms after both Doxo and Nutlin treatments (Figure 2d ). This observation suggests that modulation of translation efficiency might reinforce the activation of p53-dependent apoptosis, a process that could be important given the generally weaker transcriptional control of p53 target genes in the apoptosis group. 24 We validated by qPCR TRIAP1, 25 TRAF4 26 and GADD45G 27 (the full list of genes is presented in Supplementary Figure S3A ). According to ChIP-seq data on MCF7 cells, these genes are direct p53 targets. 28 For all of them, the increase at the polysomal level, especially after Nutlin treatment, was confirmed at both time points. For GADD45G, high level of induction was observed also in the MCF7shp53 cells (Figure 2e) .
Overall, we conclude that even if there was a weak modulation at the total mRNA level, p53 or p53-inducing treatments enhanced the translation of these apoptotic genes.
p53 as a master regulator of translation control S Zaccara et al p53 activation reduced the subpolysomal mRNA levels of DDX17, SRSF1, TARDBP and XRCC2. Relative translation efficiency can decrease by inhibiting translation without impacting mRNA stability, or by destabilizing mRNAs. Given that p53 controls the expression of many miRNAs and RBPs, 12 it could indirectly impact both mechanisms. DEGs that were selectively downregulated in the sub fraction but did not change in translation might be considered as candidate targets for a regulation process that targets more selectively mRNA molecules not engaged in translation (Figure 3a) . Following Doxo and Nutlin treatments, we observed, respectively, 305 and 160 subpolysomal downregulated DEGs (Supplementary Table S1C ) and 81 were common to the two groups. (Figure 3a) . 'Mitosis' was the mostly enriched functional category, among which XRCC2 29 was also validated by qPCR (Figure 3c ). mRNA-processing categories, such as RNA splicing, were also enriched ( Figure 3b) ; (Supplementary Figure S3B) . As we were interested in how p53 might modulate post-transcriptional mechanisms, we also selected three RBPs-SRSF1, DDX17 and TARDBP-for further qPCR validation. DDX17 and SRSF1 mRNAs were confirmed to be downregulated in sub but did not change in tot nor pol after Nutlin treatment in MCF7vector cells. On the contrary, Doxo treatment led to a less-evident down-modulation in the pol fraction that generally was p53-independent (downregulation in the MCF7shp53 cells). Changes in DDX17 and SRSF1 protein levels were investigated ( Figure 3d ). In general, protein levels were more in agreement with their matched pol changes at the 16 h time point. Moreover, SRSF1 was consistently upregulated in MCF7shp53 at 16 h post Nutlin treatment, confirming mRNA data and literature reports. p53 activation leads to translational inhibition of genes involved in mRNA processing and nucleotide binding, including YBX1. Although a reduction in subpolysomal RNA can be interpreted as evidence of reduced mRNA stability, lower polysomal RNA can be a hallmark for decreased translation efficiency of specific mRNAs.
Hence, we examined DEGs that were repressed in polysomal fraction, but did not change in total mRNA ( YBX1 was chosen for validation also because of its reported interaction with p53. 31 Its mRNA was significantly downregulated in polysomal RNA, more than in the total RNA, with a p53-dependent shift from the polysomal to the subpolysomal fraction ( Figure 4c ). The same trend was observed after 8 h, but only in the Doxo treatment. Moreover, the reduction in pol mRNA corresponds to a reduction in YBX1 protein level (Figure 4d ). The YBX1 transcript was found to have a 5 0 -terminal oligopyrimidine tract-like mRNA that is suppressed in the polysomal fraction after mTOR inhibition. 32 Furthermore, p53 can negatively modulate the mTOR pathway via the upregulation of Sestrins (SESN1-2).
33 SESN1 was among the coupled upregulated DEGs that we identified (Supplementary Table S1A ). As apparently p53 could impact on YBX1 mRNA through the mTOR pathway, we examined the impact of Doxo and Nutlin treatments on mTOR activity in comparison with two mechanistically different mTOR inhibitors rapamycin (an allosteric mTORC1 inhibitor) and Torin1 (a selective ATP-competitive mTOR inhibitor) as controls. The amount of p-4EBP1 was reduced by Torin1 and, to a limited extent, by rapamycin, but also by Doxo or Nutlin treatment in MCF7vector cells (Figure 4e ). Although YBX1 protein levels were markedly lower after Torin1 and rapamycin treatment independently from p53 status, the reduction was even more evident after both Doxo and Nutlin treatment in MCF7vector cells. This was despite the apparent lower inhibition of mTOR in MCF7shp53 cells, based on p-4EBP1 levels. Collectively, these results suggest an additional mTOR pathwayindependent, p53-dependent mechanism of YBX1 translational regulation.
We searched for published evidence of RBPs or miRNAs that could modulate YBX1 mRNA translation/stability. YBX1 was reported as a target of miR-137 in multidrug-resistant MCF7/ADAM cells, 34 but we were unable to detect miR-137 in our cell lines, both in treated and untreated conditions. On the basis on a recent CLASH analysis, 35 miR-34a, a p53-target miRNA, 12 was found to bind YBX1 3 0 UTR. We confirmed that Doxo and Nutlin increased miR-34a expression only in MCF7vector cells (Supplementary Figure S4A) . Moreover, miR-34a ectopic overexpression led to a reduction in YBX1 protein ( Figure 4f ; Supplementary Figure S4B ). Vice versa, upon inhibition of miR-34a, YBX1 levels were slightly increased in the mock condition and were reduced less by Doxo, but not by Nutlin, treatment (Figure 4g ; Supplementary Figure S4C ). The conditions tested were mock, doxorubicin (Doxo, 1.5 mM) and nutlin-3a (Nutlin, 10 mM) after 16 h of treatment. The subpolysomal fractions (sub: free RNA, small-40S and large-60S and monosomes-80S) and the polysomal fractions (pol) were separated. Sub and pol fractions (see numbers on x-axis) were combined in two separated tubes for RNA extraction. (b) Scatter-plots representing transcriptional and translational log 2 fold changes. Spearman correlation was calculated. DEGs in each category (transcriptome only, translatome only and homodirectional changes) are classified according to log 2 fold change 41 and o À 1 for induced and repressed genes, respectively, and Benjamini-Hochberg corrected P-value o0.05. Genes without significant changes are shown in gray. (c) Venn diagrams showing the level of coupling/ uncoupling for upregulated (up) and downregulated (down) DEGs after Doxo and Nutlin treatment. The green overlapping areas represent coupled DEGs that are enriched in all conditions: total RNA (tot), subpolysomal fraction (sub) and polysomal fraction (pol). (d) Coupled DEGs are mainly involved in the p53 pathway. Ingenuity pathways analysis (IPA) was performed on coupled DEGs after Doxo and Nutlin treatment and each of these genes is considered by IPA according to their log 2 fold change and BH corrected P-value, integrating up-and downregulated DEGs (up and down). Results on the coupled DEGs that are common to both Doxo and Nutlin treatments are also presented (common coupled DEGs). The y-axis displays the significance of the association between DEGs and the canonical pathways measured by Fisher's exact test. A P-value cutoff of 0.05 was used to identify significantly enriched pathways. The plot shows four among the most enriched pathways. (e) Relative expression levels of three established p53 target genes. MCF7vector cells were treated with Doxo and Nutlin for 8 h (upper plots) or 16 h (lower plot). MDM2, p21 and PUMA transcript levels were validated by qPCR in total RNA (tot), subpolysomal (sub) and polysomal (pol) fractions as positive controls. To establish p53 dependence, all experiments were conducted also in MCF7shp53 cells. Data are plotted relative to each mock condition and three reference genes. n ¼ 3. Means±S.D. are shown. *Po0.05. The basal expression levels in each RNA fraction are presented in Supplementary Table S7 p53 as a master regulator of translation control S Zaccara et al 
Therefore, an additional effect between p53-dependent miR-34a overexpression and p53-related reduction in the mTOR activity on YBX1 can be hypothesized. Functional categories Actinin p53 as a master regulator of translation control S Zaccara et al (DDX17, SRSF1, TARDBP and YBX1). By binding to their target mRNAs, RBPs could in turn contribute to the tuning of the p53-induced responses both at the transcriptional and translational levels. We chose SRSF1 and YBX1 to explore these potential regulatory modules by an siRNA approach, as they both control cell proliferation, cell-cycle progression and apoptosis 36, 37 (Figure 4h ). We confirmed data indicating that SRSF1 reduction leads to a lower stabilization of p53 protein and to lower induction of p21. 30, 38 We then examined c-MYC protein levels, given that c-MYC translation is reported to be upregulated by YBX1, 39 and SFSRF1 depletion was associated with reduced c-MYC oncogenicity. 36 Interestingly, silencing SRSF1 led to a concomitant decrease in YBX1 protein and even more so in the c-MYC protein. On the contrary, YBX1 silencing did not impact on SRSF1 or c-MYC protein levels in the mock condition.
CPEB4 and hnRNPD, mediators of translational control, are new p53 transcriptional targets. General RNA sequence features of the 5 0 and 3 0 UTR as well as coding sequence (CDS) influence post-transcriptional regulation of each mRNA. 40, 41 In order to identify potential posttranscriptional regulatory sequences embedded in the transcripts of our DEGs, we performed a distribution analysis of the length and the GC content of their 5 0 UTR, CDS and 3 0 UTR regions (Figure 5a ). When compared with the background distribution of the whole set of human genes, translatome upregulated DEGs showed significantly shorter CDS regions and higher GC content, both in the CDS and the UTRs. On the contrary, coupled downregulated genes showed a decreased GC content, more significantly in the 3 0 UTR region. UTR sequences of our DEGs were analyzed for the enrichment of specific regulatory elements using experimental annotation contained in the Atlas of regulatory UTR activity 2 (AURA 2) 42 ( Figure 5b) ; (Supplementary Figure S5) . Target mRNAs of hnRNP-A1, -C and -F were enriched among downregulated DEGs. Conversely, hnRNPD (AUF1)-binding sites were enriched among upregulated uncoupled DEGs for both Doxo and Nutlin treatments (BH P-value: 0.00027). Furthermore, our array data identified hnRNPD to be a downregulated coupled DEG upon Doxo treatment, a result confirmed by qPCR (Figure 5c ). Hence, hnRNPD should be included in the growing list of p53 target genes coding for RBPs, also considering ChIP-seq data. 43 ZNF469, ZNF488 and CPEB4 were instead upregulatedcoupled RBP DEGs common to both treatments and CPEB4 was validated by qPCR. As already reported by ChIP-seq data, 28, 43 we confirm that CEBP4 is a direct p53 target gene. Other groups of transcriptionally/translationally uncoupled genes are described in Supplementary Figure S6 .
Discussion
Genome-scale transcriptome analyses have been instrumental in describing the p53 gene response networks under a variety of stress responses. 28 Nevertheless, the mechanism defining which cellular response is adopted remains poorly characterized. 25 Here, we describe post-transcriptional gene expression control as an additional dimension to potentially shape the p53-directed gene response. Moreover, the global implications of several RBPs on that mechanism are also taken into account, given their involvement in mRNA translation. Quantitative proteomics would theoretically be an ideal tool to assess the p53-dependent translational output. Nevertheless, the coverage of proteomic studies is still a limiting factor. 44 In our approach the translatome can be considered as a proxy for the proteome, although the experimental methods maintain the sensitivity typical of RNA expression studies.
To shape the downstream response networks p53 modulates RBPs that act as molecular sieves. Guided by the comparison of transcriptome and translatome data, but also considering DEGs within the free cytoplasmic pool (sub), we identified a number of RBPs that could be regulated by either Doxo (67 RBPs) or nutlin-3a (30 RBPs) or would be common to both treatments (22) (Supplementary  Table S4 ). These 22RBPs are primary candidates for p53-directed control. Indeed, in the validation experiments GAPDH was used as reference protein for loading control, and is the same used as loading control for DDX17 in Figure 3d . (e) Western Blot analysis of MCF7vector and MCF7shp53 cell extracts after treatment with Doxo, Nutlin, rapamycin (Rapa) and Torin1. Protein levels of YBX1, total 4EBP1 and phosho(p-) 4EBP1 were measured as mTOR inhibition would lead to a reduction of 4EBP1 phosphorylation (p-4EBP1) and the consequent inhibition of cap-dependent translation. As control, p53 protein levels were measured. p53 is stabilized after 16 h of treatment with Doxo and Nutlin, whereas the treatment with mTOR inhibitors does not have an impact on p53 protein levels. GAPDH was used as a reference protein for loading control. For YBX1, numbers above the immunoreactive bands represent the relative amount of proteins normalized against both the reference protein and the mock condition (set to 1 separately for each cell line). (f) Ectopic overexpression of miR-34a in MCF7vector cell line. The empty miR-expression plasmid psiUx condition was used as negative control. miR-636 was overexpressed as an additional control of miR-34a specificity. GAPDH was used as a reference protein for loading control. (g) YBX1 protein levels in MCF7vector cells transfected with the negative Control A or an LNA-antagomiR-34a and treated after 48 h with Doxo or Nutlin. Actinin was used as a reference protein for loading control. Numbers above the immunoreactive bands represent the relative amount of proteins normalized using both the reference protein and the mock condition in the control experiment (set to 1). (h) Western Blot analysis on MCF7vector cell extracts after silencing YBX1, SRSF1 or scramble control, either in the mock condition or after Doxo or Nutlin treatment. Protein levels of YBX1 and SRSF1 confirm the silencing. c-MYC protein levels were measured because it is a recognized downstream target of both YBX1 and SRSF1. As additional controls, p53 as well as p21 levels were measured. Actinin was used as a reference protein for loading control we confirmed YBX1, SRSF1, DDX17, TARDBP, HNRNPD and CEBP4 as targets of p53-dependent modulation at the total mRNA or polysomal mRNA levels or both ( Figure 6 ). In particular, we focused on targets that could directly or indirectly modulate p53 functions, either by acting on the p53 mRNA or on the mRNAs of p53 target genes. Interestingly, hnRNPD had already been reported to target and destabilize the mRNAs of p53, 45 BAX and other important cancer genes, often in a reciprocal, alternating association with HuR, an mRNA-stabilizing factor. 45 We propose that through the transcriptional downregulation of hnRNPD, p53 can engage a positive feedback and potentially also a feed-forward regulatory loop. Consistently, we found enrichment for hnRNPD target mRNAs among the group of translationally upregulated DEGs (Figure 5a) .
CPEB4 was an upregulated-coupled DEG whose enhanced expression was abated by p53 silencing. Notably, CPEB4 is a member of the CPEB family, and CPEB1, functionally related with CPEB4, was shown to sustain p53 translation, thereby participating in the activation of the senescence response. 46, 47 We suggest that p53 could impact its own translation fitness and functions via its direct target gene CPEB4.
DDX17, TARDBP, SRSF1 and YBX1 are confirmed as modulated at the post-transcriptional level. Overall, in almost all the analyses, protein levels reflect the subpolysomal or polysomal mRNA changes, suggesting that these mRNA variations could have a significant impact on the final proteome. Although TARDBP functions are still under investigation, DDX17/p72 is a putative RNA helicase 48 that by interacting with DDX5 (p68) can act as a modulator of p53-dependent transcription and DNA damage response. SRSF1 was repressed by both doxorubicin and nutlin-3a treatments particularly in the subpolysomal RNA fraction, and the p53-dependent negative modulation was apparent comparing MCF7vector with MCF7shp53 cells. As it was recently reported that SRSF1 overexpression provides resistance to oncogenic transformation via stabilization of p53, 30, 49 we propose that we have uncovered a negative feedback loop by which p53 inhibits a positive regulator.
We explored in more detail two mechanisms linking p53 activation with YBX1 mRNA and protein downregulation, namely the inhibition of the mTOR pathway 32 and the upregulation of miR-34a. 12 Although p53 can negatively impact on mTOR, via the transcriptional activation of SESN1 and SESN2, 33 the high dependency of mTOR function on the cell metabolic state can also influence our results. The dynamics by which p53 modulates all these RBPs is an additional, critical point. Here, we measured the expression of these genes also after 8 h of treatments to begin exploring this issue. Temporal differences in p53 stabilization upon doxorubicin and nutlin-3a treatments have been already reported 50 and are confirmed by our analysis. Overall, the qPCR results revealed correlations (e.g., p21, PUMA, TRIAP1, TRAF4, XRCC2, hnRNPD and CPEBP4) as well as differences (MDM2, PHPT1, TP53RK, GADD45G, DDX17, SRSF1, TARDBP and YBX1), between the two time points and also between mRNA and protein levels.
Further investigations are needed to clarify the specific impact of RBPs on post-transcriptional regulation after p53 activation. In our experiments SRSF1 silencing led to a decrease also in YBX1 protein levels, suggesting a cross-talk between the two RBPs via unexplored mechanisms, and this resulted in down-modulation of c-MYC. Hence, p53-dependent negative regulation of both YBX1 and SRSF1, [33]
[31]
[30]
[45] [46] [ ] reference Apoptosis can be regulated also at the level of translation efficiency of p53 target genes. Gene ontology of DEGs that were uncoupled and upregulated only in the polysomal fraction revealed an enrichment for the term 'apoptosis', which was even more significant in cells treated with nutlin-3a. This finding uncovers a new layer of complexity in the modulation of the classical p53-dependent apoptosis (Supplementary Figure S7) . Several studies have shown that transcriptional activation of apoptosis gene targets can be influenced by selective cofactors or specific post-translational modifications of the p53 protein. 24 We suggest that translational controls may promote the synthesis of those pro-apoptotic proteins contributing to the actual induction of programmed cell death. Recently, Ribo-seq was used to profile MCF7 cells treated with nutlin-3a. 52 Ribo-seq maps ribosome-protected fragments, but, unlike polysomal profiling, it does not separate actively translating polysomes from monosomes (80S), nor does it address subpolysomal RNA. Consistently with our results, downregulation of cell-cycle genes was observed but the modulation of apoptosis or mRNA-processing pathways was not apparent in Ribo-seq data.
In summary, our analysis of uncoupled mRNAs, namely mRNAs undergoing translational control, reveals a large number of new indirect p53-regulated targets that would not have been identified through a traditional transcriptome study. On the basis of the functions of these genes, it becomes apparent that selectivity at the level of mRNA translation, in addition to transcriptional selectivity, is a critical contributing factor in the shaping of p53-directed responses and at least six RBPs directly or indirectly modulated by p53 may be implicated. Our study opens up a scenario where further investigations will clarify the impact of p53-dependent post-transcriptional regulation as well as the involvement of RBPs on cellular outcomes.
Materials and Methods
Cell lines and culture conditions. MCF7 cells stably expressing an shRNA targeting p53 (MCF7shp53) or control cells (MCF7vector) were kindly provided by Dr Agami. 20 Cells were normally maintained in RPMI (Gibco, Life Technologies, Milan, Italy) supplemented with 10% FBS, antibiotics (100 units/ml penicillin plus 100 mg/ml streptomycin) and 2 mM L-glutamine. Puromycin (SigmaAldrich, Milan, Italy) was used to maintain the selection, at 0.5 mg/ml as final concentration.
Polysomal RNA fractionation and extraction. MCF7vector cells (3.5 Â 10 6 ) were seeded into 10 cm tissue culture dishes and allowed to reach 70-80% confluence before treatment with 1.5 mM doxorubicin (Doxo) or 10 mM nutlin-3a (Nutlin). Doxo was purchased from Sigma-Aldrich, whereas nutlin-3a was obtained from Alexis Biochemicals (Enzo Life Science, Exeter, UK). After 8 or 16 h, polysomal separation was performed as previously described. 53 Briefly, samples were loaded in 15-50% linear sucrose gradients, ultra-centrifuged and fractionated with an automated fraction collector. All the fractions containing subpolysomal or polysomal RNA were identified and pooled in two separate tubes. RNA was purified by extraction with 1 volume of phenol-chloroform and adding a washing step in 70% v/v ethanol in order to remove phenol contaminations. DNAse treatment (RNase-Free DNase Set, Qiagen, Hilden, Germany) was performed to remove DNA contamination after the RNA extraction. Three biological replicates were performed. For validation studies, all these steps were repeated also for the MCF7shp53 cell line, seeding 2 Â 10 6 cells/dish.
Total RNA extraction. MCF7vector and MCF7shp53 cell lines were seeded into six-well plates and allowed to reach 70-80% of confluency before treating with 1.5 mM Doxo or 10 mM Nutlin. After 8 or 16 h of treatment, cells were harvested and total RNA was extracted using the Agilent Total RNA Isolation Mini Kit (Agilent Technologies, Milan, Italy) according to the manufacturer's instructions. In-column DNAse treatment (RNase-Free DNase Set, Qiagen) was performed to remove DNA contamination during the extraction. Three biological samples were analyzed.
Microarray hybridization and data analysis. Purity of all extracted RNAs (A260/A280 value of 1.8-2.1) and concentrations were measured using the Nanodrop spectrophotometer. An additional quality control was performed with the Agilent 2100 Bioanalyzer (Agilent Technologies) discarding RNA preparations with RIN (RNA integrity number) value o8. mRNAs extracted after 16 h of treatment with Doxo or Nutlin were hybridized to an Agilent-014850 Whole Human Genome Microarray 4x44K G4112F-Probe following the manufacturer's protocol. Raw data and procedures were deposited in Gene Expression Omnibus (GSE50650). That output was analyzed with the tRanslatome package 54 using the Limma method (http://www.bepress.com/sagmb/vol3/iss1/art3) comparing each treatment of every tested RNAs with the mock condition. Moreover, Supplementary Table S5 shows the detailed list of all our DEGs. For all further analysis on DEGs, two thresholds were set for each comparison: (1) log 2 (fold change) 41 and o À 1 for upregulated and downregulated genes, respectively; (2) Benjamini-Hochberg (BH) corrected P-value o0.05.
Gene ontology and pathway analysis of DEGs. Gene-annotation enrichment analysis for all our selected categories of coupled or uncoupled DEGs was performed with the DAVID resource. 55 The significance of overrepresentation was determined at a false discovery rate of 5% with BH multiple testing correction and an enrichment score 41.5. All pathways analyses were performed using ingenuity pathway analysis (www.ingenuity.com). Only direct interactions were considered in setting parameters.
Analysis of UTR sequence features. UTR and CDS sequences were downloaded from the UCSC Genome Browser (http://genome.ucsc.edu/), assembly GRC37/hg19. For each HGNC gene the longest transcript variant was selected as representative of the gene. Distribution analysis was performed on the length and GC content of 5 0 UTR, CDS and 3 0 UTR regions of the lists of DEGs. All the distributions were compared with the background distribution corresponding to the whole set of human genes, and significant shifts were identified with the Mann-Whitney test, selecting a 0.01 significance threshold on the resulting P-value.
Analysis of 5
0 -3 0 UTRs and of RBP genes. The AURA 2 database (http://aura.science.unitn.it/) was used to perform the analysis of the enrichment of regulatory elements at the 5 0 -3 0 UTR of coupled or uncoupled DEGs. Given that AURA 2 is a database containing only experimentally validated post-transcriptional interactions at the UTR level, we used AURA to select enriched RBPs for further validations. The presented enrichment P-values were adjusted for multiple testing with the BH-method. We matched our DEG classes with a restricted RBPs' list to obtain the number of RBP genes that were modulated after Doxo and nutlin-3a treatments. The restricted list was compiled including all canonical RBPs (i.e., proteins containing at least one recognized RBP motif), translation factors and non-canonical RBPs reported in previous studies. 56, 57 RT-qPCR reaction. cDNA was generated from 1 mg of RNA using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Milan, Italy) in 20 ml final volume following manufacturer's instructions. All qPCR assays were performed on a CFX Touch Real-Time PCR Detection System (Bio-Rad, Milan, Italy) in a 384-well plate format. Assays contained 2X KAPA Probe FAST qPCR Master Mix (Kapa Biosystems, Resnova, Rome, Italy), 20 Â PrimeTime ZEN DoubleQuenched Probes Assay (IDT, Tema Ricerca, Bologna, Italy) and 25 ng of cDNA. Primers are all commercially available according to their catalog number. In addition, we validated some targets using the 2 Â KAPA SYBR FAST qPCR Kit (Kapa Biosystems, Resnova) and specific primers purchased from Eurofins (MWG, Operon, Ebersberg, Germany). The list of primers is presented in p53 as a master regulator of translation control S Zaccara et al
